Development & Commercialisation of two novel vaccines Intranasal Covid-19 Vaccine and RTS, S Malaria Vaccine

Accessibility Controls

M/s Sapigen Biologix Pvt. Ltd., Hyderabad, Telangana

Focused on developing Indiaâ€™s first intranasal Covid-19 vaccine and RTS, S Malaria vaccine, with a state-of-the-art facility in Bhubaneswar.

Thrust Areas

Medical Sciences

Focus Area

Vaccines, Healthcare

Sanction Amount

₹ â‚¹311.30 Cr (TDB assistance â‚¹100.00 Cr)

Status

Commercialisation stage

Source Title

Technology Development Board (TDB)

Status

Commercialisation stage

TRL: Technology Readiness Level

TRL 9

Company Transferred To

Yes

Accessibility Controls